Abstract
The development of a series of potent and selective antitumour agents, the 2-(4- aminophenyl)benzothiazoles, is described. The original lead compound in this series, CJM 126, exhibits nanomolar in vitro activity against certain human breast cancer cell lines. Structure-activity relationship studies within this simple antitumour benzothiazole pharmacophore revealed that 2-(4-aminophenyl) benzothiazoles bearing a 3- methyl, 3-bromo, 3-iodo or 3-chloro substituent are especially potent, extending the spectrum of in vitro antitumour activity to ovarian, lung, renal and colon carcinoma cell lines with a remarkable selectivity profile (NCI analysis). Other interesting features of this series include the highly unusual transient biphasic dose response relationship and possible unique mechanism of action (NCI COMPARE analysis). 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) has been selected as the lead compound in this series on the basis of superior in vivo results.
Current Medicinal Chemistry
Title: The Discovery of the Potent and Selective Antitumour Agent 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) and Related Compounds
Volume: 8 Issue: 2
Author(s): T. D. Bradshaw, M.F. G. Stevens and A. D. Westwell
Affiliation:
Abstract: The development of a series of potent and selective antitumour agents, the 2-(4- aminophenyl)benzothiazoles, is described. The original lead compound in this series, CJM 126, exhibits nanomolar in vitro activity against certain human breast cancer cell lines. Structure-activity relationship studies within this simple antitumour benzothiazole pharmacophore revealed that 2-(4-aminophenyl) benzothiazoles bearing a 3- methyl, 3-bromo, 3-iodo or 3-chloro substituent are especially potent, extending the spectrum of in vitro antitumour activity to ovarian, lung, renal and colon carcinoma cell lines with a remarkable selectivity profile (NCI analysis). Other interesting features of this series include the highly unusual transient biphasic dose response relationship and possible unique mechanism of action (NCI COMPARE analysis). 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) has been selected as the lead compound in this series on the basis of superior in vivo results.
Export Options
About this article
Cite this article as:
Bradshaw D. T., Stevens G. M.F. and Westwell D. A., The Discovery of the Potent and Selective Antitumour Agent 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) and Related Compounds, Current Medicinal Chemistry 2001; 8 (2) . https://dx.doi.org/10.2174/0929867013373714
DOI https://dx.doi.org/10.2174/0929867013373714 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association of Use of the Oral Contraceptive Pill (OCP) with the Expression
Pattern of Different Molecular Subtypes of Breast Cancer
Current Women`s Health Reviews Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA Therapeutically-induced Autoantibodies in Patients Treated with Recombinant Hematopoietic Growth Factors: A Brief Summary
Current Pharmaceutical Design Graphical Abstracts
Letters in Drug Design & Discovery Nanomedicine: Potential Devices for Diagnostics
Recent Patents on Nanomedicine COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Stem Cell Therapy for Spinal Cord Injury
Current Medicinal Chemistry PPARγ-targeting Potential for Radioprotection
Current Drug Targets Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats
Drug Metabolism Letters Emerging Restorative Treatments for Parkinsons Disease: Manipulation and Inducement of Dopaminergic Neurons from Adult Stem Cells
CNS & Neurological Disorders - Drug Targets Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Subject Index To Volume 2
Current Immunology Reviews (Discontinued) Comprehensive Profiling of the Low Molecular Weight Proteins and Peptides in Weak Cation Exchange Beads Human Serum Retentate
Protein & Peptide Letters Synthesis and Biological Evaluation of Macamides Derivatives as Potent Inhibitors of Breast Cancer Cell MCF-7
Letters in Drug Design & Discovery CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review
Current Pharmaceutical Biotechnology Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Polymer Nanoparticles - A Novel Strategy for Administration of Paclitaxel in Cancer Chemotherapy
Current Medicinal Chemistry